Repligen Analyst Ratings
Deutsche Bank Upgrades Repligen to Buy, Lowers Price Target to $155
RBC Cuts Price Target on Repligen to $190 From $221, Maintains Outperform Rating
Repligen Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)
JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $200
Repligen Analyst Ratings
UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating
Repligen (RGEN) Gets a Buy From RBC Capital
Craig-Hallum Sticks to Their Buy Rating for Repligen (RGEN)
RBC Capital Remains a Buy on Repligen (RGEN)
RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immuneering (IMRX), Halozyme (HALO) and Repligen (RGEN)
Repligen Analyst Ratings
Deutsche Bank Adjusts Repligen Price Target to $180 From $175, Maintains Hold Rating
RBC Raises Price Target on Repligen to $225 From $200, Keeps Outperform Rating
Repligen (RGEN) Receives a Buy From RBC Capital
Repligen (RGEN) Gets a Buy From Craig-Hallum
Keybanc Maintains Overweight on Repligen, Raises Price Target to $220
Repligen Analyst Ratings